Quanterix Corp (QTRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quanterix Corp (QTRX) has a cash flow conversion efficiency ratio of -0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.25 Million) by net assets ($314.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Quanterix Corp (QTRX) balance sheet quality index to measure how much of total assets are equity-financed.
Quanterix Corp - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Quanterix Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Quanterix Corp cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quanterix Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quanterix Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IFGL Refractories Limited
NSE:IFGLEXPOR
|
0.007x |
|
Alumil Aluminium Industry S.A
AT:ALMY
|
0.021x |
|
Ellsworth Convertible Growth & IF
NYSE MKT:ECF
|
-0.076x |
|
Media Nusantara Citra Tbk PT
JK:MNCN
|
0.008x |
|
NX Filtration Holding BV
AS:NXFIL
|
-0.009x |
|
Hirequest Inc
NASDAQ:HQI
|
0.097x |
|
BioInvent International AB
ST:BINV
|
0.082x |
|
Saturn Metals Ltd
AU:STN
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Quanterix Corp (2015–2024)
The table below shows the annual cash flow conversion efficiency of Quanterix Corp from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Quanterix Corp (QTRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $330.04 Million | $-35.16 Million | -0.107x | -97.26% |
| 2023-12-31 | $349.96 Million | $-18.90 Million | -0.054x | +59.95% |
| 2022-12-31 | $357.93 Million | $-48.27 Million | -0.135x | -24.13% |
| 2021-12-31 | $440.95 Million | $-47.91 Million | -0.109x | +4.15% |
| 2020-12-31 | $206.12 Million | $-23.36 Million | -0.113x | +44.31% |
| 2019-12-31 | $128.66 Million | $-26.19 Million | -0.204x | +70.55% |
| 2018-12-31 | $41.56 Million | $-28.72 Million | -0.691x | -105.93% |
| 2017-12-31 | $65.87 Million | $-22.11 Million | -0.336x | +74.51% |
| 2016-12-31 | $13.48 Million | $-17.74 Million | -1.317x | -259.82% |
| 2015-12-31 | $-15.20 Million | $-12.52 Million | 0.824x | -- |
About Quanterix Corp
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa … Read more